NASDAQ:GLUE Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis $4.79 -0.16 (-3.23%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.79 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Monte Rosa Therapeutics Stock (NASDAQ:GLUE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GLUE alerts:Sign Up Key Stats Today's Range$4.78▼$4.9750-Day Range$3.97▼$5.9652-Week Range$3.50▼$12.40Volume578,534 shsAverage Volume439,912 shsMarket Capitalization$294.63 millionP/E Ratio59.88Dividend YieldN/APrice Target$15.33Consensus RatingModerate Buy Company Overview Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts. Read More Monte Rosa Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreGLUE MarketRank™: Monte Rosa Therapeutics scored higher than 25% of companies evaluated by MarketBeat, and ranked 814th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingMonte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMonte Rosa Therapeutics has received no research coverage in the past 90 days.Read more about Monte Rosa Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($1.49) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monte Rosa Therapeutics is 59.88, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Monte Rosa Therapeutics is 59.88, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.67.Price to Book Value per Share RatioMonte Rosa Therapeutics has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Monte Rosa Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.40% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 20.1, which indicates bearish sentiment.Change versus previous monthShort interest in Monte Rosa Therapeutics has recently increased by 0.68%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMonte Rosa Therapeutics does not currently pay a dividend.Dividend GrowthMonte Rosa Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.40% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 20.1, which indicates bearish sentiment.Change versus previous monthShort interest in Monte Rosa Therapeutics has recently increased by 0.68%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for GLUE on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.90% of the stock of Monte Rosa Therapeutics is held by insiders.Percentage Held by Institutions79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Monte Rosa Therapeutics' insider trading history. Receive GLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GLUE Stock News HeadlinesMonte Rosa doses first subjects in trial of MRT-8102 for inflammatory conditionsJuly 22, 2025 | msn.comMonte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory DiseasesJuly 21, 2025 | globenewswire.comThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should buy in this market, this token might just be it. | Crypto 101 Media (Ad)Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader MedicinesJuly 3, 2025 | globenewswire.comMonte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory DiseasesJune 10, 2025 | globenewswire.comMonte Rosa Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comMonte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business UpdatesMay 8, 2025 | globenewswire.comMonte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast CancerApril 28, 2025 | globenewswire.comSee More Headlines GLUE Stock Analysis - Frequently Asked Questions How have GLUE shares performed this year? Monte Rosa Therapeutics' stock was trading at $6.94 at the beginning of 2025. Since then, GLUE stock has decreased by 31.0% and is now trading at $4.79. How were Monte Rosa Therapeutics' earnings last quarter? Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) released its quarterly earnings data on Thursday, May, 8th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.81. The firm had revenue of $84.93 million for the quarter, compared to analysts' expectations of $13.57 million. Monte Rosa Therapeutics had a trailing twelve-month return on equity of 2.65% and a net margin of 3.86%. When did Monte Rosa Therapeutics IPO? Monte Rosa Therapeutics (GLUE) raised $211 million in an IPO on Thursday, June 24th 2021. The company issued 11,700,000 shares at a price of $17.00-$19.00 per share. Who are Monte Rosa Therapeutics' major shareholders? Monte Rosa Therapeutics' top institutional investors include CWM LLC (0.05%), Wealth Enhancement Advisory Services LLC (0.03%), Pallas Capital Advisors LLC (0.02%) and Brighton Jones LLC (0.02%). Insiders that own company stock include Versant Venture Capital Vi, L, Edmund Dunn and Chandra P Leo. View institutional ownership trends. How do I buy shares of Monte Rosa Therapeutics? Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Monte Rosa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Monte Rosa Therapeutics investors own include AU Optronics (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/08/2025Today8/02/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLUE CIK1826457 Webwww.monterosatx.com Phone617-949-2643FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Price Target for Monte Rosa Therapeutics$15.33 High Price Target$19.00 Low Price Target$10.00 Potential Upside/Downside+220.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$0.08 Trailing P/E Ratio59.88 Forward P/E RatioN/A P/E GrowthN/ANet Income-$72.70 million Net Margins3.86% Pretax Margin5.93% Return on Equity2.65% Return on Assets1.65% Debt Debt-to-Equity RatioN/A Current Ratio5.61 Quick Ratio5.61 Sales & Book Value Annual Sales$75.62 million Price / Sales3.90 Cash FlowN/A Price / Cash FlowN/A Book Value$3.63 per share Price / Book1.32Miscellaneous Outstanding Shares61,510,000Free Float57,266,000Market Cap$294.63 million OptionableOptionable Beta1.42 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:GLUE) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.